The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Over the past two decades, the role of vitreomacular adhesion in vitreomacular interface pathologies, such as vitreomacular traction syndrome, epiretinal membrane and macular hole, has been ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

DUBLIN--(BUSINESS WIRE)--The "Ophthalmic Lasers Market - Global Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Ophthalmic Lasers Market was valued at ...